Spartina Biotechnologies

led by experts at SPARTINA BIOTECHNOLOGIES

Introducing Celerna™
RNA Interference Technology

Celerna™ is a single-celled system for the production, packaging and targeted delivery of therapeutic RNAs.

ABOUT SPARTINA BIOTECHNOLOGIES

Disrupting The RNA Therapeutics Industry

Spartina Biotechnologies is an early-stage biotech company that is developing and implementing a new platform, Celerna™, for the precision delivery of RNA molecules to specific cells and organs to stop the spread of viruses.

Natural RNAi Technology

Natural-like RNA molecules are delivered to the cells that viruses are able to infect, destroying the virus’s RNA.

Blocking Further Replication

This is done without affecting the human gene’s RNA, and blocks further replication and spread of the virus.

Once developed, the Celerna™ platform can be used for broad application in the treatment of: 

ABOUT SPARTINA BIOTECHNOLOGIES

Disrupting The RNA Therapeutics Industry

Spartina Biotechnologies is an early-stage biotech company that is developing and implementing a new platform, Celerna™, for the precision delivery of RNA molecules to specific cells and organs to stop the spread of viruses.

Natural RNAi Technology

Natural-like RNA molecules are delivered to the cells that viruses are able to infect, destroying the virus’s RNA.

Blocking Further Replication

This is done without affecting the human gene’s RNA, and blocks further replication and spread of the virus.

Once developed, the Celerna™ platform can be used for broad application in the treatment of: 

THE Celerna™ PLATFORM

Our First Application:
COVID-19

To this day, COVID-19 remains a global medical priority. Spartina Biotechnologies is developing the exosomes-based RNA delivery system for treatment of SARS-CoV2 infection. The Celerna™ system will deliver RNA molecules to all cells susceptible to SARS-CoV-2 infection and destroy the virus’s RNA, blocking further replication, and spread of the virus.

THE Celerna™ PLATFORM

Our First Application:
COVID-19

To this day, COVID-19 remains a global medical priority. Spartina Biotechnologies is developing the exosomes-based RNA delivery system for treatment of SARS-CoV-2 infection. The Celerna™ system will deliver RNA molecules to all cells susceptible to SARS-CoV-2 infection and destroy the virus’s RNA, blocking further replication, and spread of the virus.